Brought to you by 
Schering-Plough gets rights to Sequus' Caelyx; later ends
23 Jun 2014
Executive Summary
Schering-Plough licensed exclusive worldwide marketing and development rights outside of the US, Japan, and several small markets to Sequus' (liposomes) oncology drug Caelyx (pegylated liposomal doxorubicin HCl).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Liposomes
Deal Status
- Concluded
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schering-Plough gets rights to Sequus' Caelyx; later ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice